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Abstract: During these last 15 years, drug discovery strategies have essentially focused on identifying small molecules able to inhibit 
catalytic sites. However, other mechanisms could be targeted. Protein-protein interactions play crucial roles in a number of biological 
processes, and, as such, their disruption or stabilization is becoming an area of intense activity. Along the same line, inhibition of protein-
membrane could be of major importance in several disease indications. Despite the many challenges associated with the development of 
such classes of interaction modulators, there has been considerable success in the recent years. Importantly, through the existence of pro-
tein hot-spots and the presence of druggable pockets at the macromolecular interfaces or in their vicinities, it has been possible to find 
small molecule effectors using a variety of screening techniques, including combined virtual ligand-in vitro screening strategy. Indeed 
such in silico-in vitro protocols emerge as the method of choice to facilitate our quest of novel drug-like compounds or of mechanistic 
probes aiming at facilitating the understanding of molecular reactions involved in the Health and Disease process. In this review, we 
comment recent successes of combined in silico-in vitro screening methods applied to modulating macromolecular interactions with a 
special emphasis on protein-membrane interactions. 
Keywords: Virtual screening, structure-based drug design, drug discovery, protein-protein interaction, protein-membrane inter-
action. 
INTRODUCTION 
  Among the over 30,000 unique protein sequences present 
in the Human proteome, only 1% have been successfully 
targeted with small drug molecules [1]. Most recent small 
molecule drug discovery initiatives are been used to develop 
and/or expand the already existing pre-clinical and clinical 
pipelines focusing on G-protein coupled receptors, nuclear 
receptors, ion channels and enzyme active sites [2]. How-
ever, key functional regulations of numerous biological 
processes involved in the pathogenesis of diseases can also 
be achieved through targeting protein-protein interactions 
(PPI), or protein-membrane, protein-RNA or protein-DNA 
interactions. For example, a recent study has estimated that 
~29% of proteins that bind another protein are potentially 
druggable [3]. Maximizing the range of proteins that can be 
targeted with small-molecule drugs is critical to fully exploit 
the wide variety of molecular targets that are encoded by the 
human genome [1]. In fact, increasing the number of poten-
tial targets will soon become critical given the fact that there 
is a significant number of disease indications with unmet 
clinical needs. The call for alternative drug targets is a prob-
lem that is also likely to worsen due to the emergence of 
clinical complications with current therapeutic drugs, world 
population aging and the birth of new diseases. These obser-
vations lead to two overlapping concepts and needs, (i) iden-
tifying and characterizing more targets, new targets or target-
ing presently known macromolecules at hitherto untargeted 
sites, and (ii) trying to understand the connections between 
the target space and the chemical space through, for instance, 
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ongoing chemogenomics/chemical biology projects [4-6]. 
Along this line of reasoning and toward the identification of 
mechanistic chemical probes or toward leads that could be 
optimized into drugs, drugging PPIs and/or exosites instead 
of catalytic sites via small drug-like molecules can be con-
sidered as a paradigm shift in drug discovery. From a bio-
logical standpoint and in favor of such initiatives, the con-
cept of inhibiting PPIs has been validated through the use of, 
for example, mini-proteins, antibodies or antagonist peptides 
(and peptide aptamers), some of which have become highly 
successful drugs [1]. However, in most situations, it would 
be desirable to design “drug-like” inhibitors instead of thera-
peutic proteins or peptides. These latter therapeutic mole-
cules usually have to be infused, a situation that is not com-
fortable for patients nor clinicians while the costs associated 
with such therapies is already intractable in many countries. 
Not in favor of the ideas of targeting macromolecular com-
plex formations or exosites are claims that impeding protein-
protein associations is difficult for energetic reasons or that 
the small organic compounds able to perform such action 
will fall outside the range of the so-called “drug-like” profile 
and therefore could not be administrated orally [2, 7]. Even 
if these observations are partially correct, among the 40,000 
to 250,000 known or predicted PPIs in humans [8, 9], there 
are strong evidences that it should be possible to target, with 
drug-like compounds, a sizable number of these interfaces 
[10]. In fact, several observations provide hope for finding 
small molecules that target protein-protein interfaces. Al-
though the interfaces are large, mutational studies show that 
only a small subset of residues contributes significantly to 
the free energy of binding [11]. Moreover, peptides selected 
to bind to one protein partner by phage display or through 
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with the other protein partner. As such, tight binding at pro-
tein-protein interfaces does not necessarily require extended 
surface contacts [11]. 
  PPI networks embody a system-level description of the 
proteome and will be invaluable for systems biology ap-
proaches to model complex processes such as signaling 
pathways [9]. Knowledge about protein-protein interactions 
will enable a better understanding of the physiology of signal 
transduction at the molecular level and the manifestation of 
multi-factorial diseases that originate from disturbances of 
overlapping pathways. A recent evaluation of the number of 
PPI in the interactome gives 250,000 interactions with only 
5-10% of pair-wise interactions being already charted [9]. Of 
these described interactions, one cannot indicate how many 
have a real and direct therapeutic potential. However, with 
tangible success stories such as p53-MDM2, Ras-Raf, XIAP-
smac (and several others), we foresee that these may be the 
forecast of more small molecule-PPI modulators to appear in 
the near future.  
  While antagonizing macromolecular interaction with 
chemical compounds is recognized by many to be challeng-
ing but possible, some researchers are still critical as to the 
feasibility of such projects and as such the question/concept 
is still under debate. The principal argument concerns the 
size of the small compounds with respect to their natural 
competitors (e.g., 1000 times bigger) and the incapacity of 
small molecule to disrupt protein-protein complexes once 
they are formed. However, if one considers that binding in 
general is as an equilibrium process between isolated mono-
mers and a multimeric complex, it is no longer reasonable to 
think that a small molecule can not bind specifically to one 
partner and prevent/stabilize association [12]. Yet, clearly, 
different types of protein complexes have been observed, 
homo- and hetero-complexes (i.e., the interaction occur be-
tween identical or non-identical chains) and obligate and 
non-obligate complexes (a related view refers to interactions 
as transient or permanent). Well-known examples can be, for 
a permanent complex, the interleukin 8 homodimer (PDB 
code 1il8), and for a non-obligate complex, the cytochrome c 
peroxidase associated with cytochrome c (PDB code 2pcb). 
Also, depending on the type of complexes (permanent, tran-
sient…), the nature of the interface usually differs, from 
somewhat hydrophobic/aromatic to a mixture of hydropho-
bic/aromatic and polar properties. As such, it is possible that 
small molecules could only target efficiently some types of 
complexes, but recent studies do not support this view and 
further work is required to fully address this question [10]. 
  Protein-protein interactions represent a vast and diverse 
group of targets for therapeutic innovation [11], yet other 
kinds of macromolecular interactions are likewise abundant 
in living organisms and many of them have been neglected 
over the years. In this article, we will comment on the dis-
covery of drug-like molecules inhibiting the transient inter-
actions between a protein and an appropriate membrane sur-
face. However, while it is important to screen as many tar-
gets as possible, it is also important to keep in mind that drug 
discovery is a costly and time-consuming process [13] and 
that screening thousands of targets and millions of small 
drug-like molecules may not be feasible through conven-
tional approaches such as High Throughput Screening 
(HTS). Consequently, methods that reduce the costs and 
speed-up the overall process have to be applied, and among 
those, in silico methodologies are becoming well-established 
in the field of drug discovery and have been applied success-
fully to numerous targets [14-18].  
  Here, we will briefly introduce the concept of targeting 
regions located outside the catalytic sites and illustrate this 
point through analysis of recent developments in the protein-
protein interaction field. The opportunities that are created in 
terms of new areas of therapeutic innovation or better under-
standing of molecular events are discussed. Then, we will 
focus on transient protein-membrane interaction; a new class 
of targets that we think should be investigated as an alterna-
tive route for the design of novel therapeutic agents. We will 
take as example our recent proof of concept study, carried 
out on the non-enzymatic coagulation factor V [19]. Along 
the present review, we will also comment on the roles that in 
silico tools can play to help prioritize targets and small 
molecules, thereby facilitating the drug discovery process 
and/or chemical biology projects. 
Screening Regions Outside the Comfort Zone in a Cost 
Effective Fashion 
  Conventionally and during the last 15 years, the search 
for lead compounds has involved HTS screening of all pos-
sible chemicals available in compound collections. Although 
the method is attractive, the hit rates are generally disap-
pointing considering the costs, the time and the need of large 
quantities of biological materials (e.g., purified proteins, 
small compounds…) [20]. The development of virtual 
screening methods allow for a more rational and efficient 
screening in many situations and indeed, virtual screening 
tools are more and more applied prior to HTS experiments. 
Yet, all scientists working in the drug discovery field know 
that in order to succeed, a combination of methods is usually 
necessary and that drug discovery requires multi-disciplinary 
team-work.  
 While  in silico screening strategies still suffer from obvi-
ous limitations, many new hits have been identified after 
application of these computer tools. In silico techniques usu-
ally involve the screening of chemical compound libraries 
(i.e., in general the compounds are available or can be pur-
chased, although in some cases the compounds can be virtual 
and will thus have to be synthesized should they be selected 
by the process). These techniques are used to predict, instead 
of measuring, the potency of a small molecule on a given 
bio-molecular target. Depending on the information avail-
able at the beginning of a screening campaign (e.g., crystal 
structure of the target, and/or knowledge of previously de-
termined chemical compounds acting on the desired target) 
two strategies can be applied: structure-based virtual screen-
ing or SBVS (i.e., docking/scoring) [14, 21-23] or ligand-
based virtual screening or LBVS [24-35] (Fig. 1). The first 
steps of SBVS approaches involve docking computations. 
These consist of placing the small molecules that are present 
in the (virtual) chemical library into a (known or predicted) 
binding pocket such that the predictions of a likely pose and 
of a relative affinity can be established at a later stage. 
LBVS, on the other hand, make use of previously identified 
chemical compounds to identify new ligands based on 2D 
and/or 3D similarity searches, and in this case, the 3D struc-
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rewarding to combine both SBVS and LBVS with other 
methods, such as NMR (Nuclear Magnetic Resonance), crys-
tallography and site directed mutagenesis. The projects and 
the first results obtained after initial screening experiments 
usually guide the selection of an appropriate set of methods 
to be used. 
 Overall,  in silico and HTS methods have been very suc-
cessful in screening catalytic sites, in part because the pocket 
to be screened is usually “druggable” (e.g., well formed 
binding region with a topology and physico-chemical prop-
erties compatible with the tight binding of a small molecule), 
although even if druggable, there are usually no easy targets. 
The situation can be significantly different though when 
screening protein-protein interfaces. For PPI, and in contrast 
to conventional druggable targets, the small molecule inhibi-
tors or stabilizers can be thought, at first, as having to inter-
act or interfere with a large interface area, often lacking a 
well formed cavity or cleft [1]. Because of this preconceived 
idea, the rational design of small molecules able to perturb 
PPI has long being thought of as an unreachable goal. How-
ever, today, several successful examples have been reported 
[36] confirming the hypothesis that small non-peptide mole-
cules can interfere with PPIs. Indeed, even at protein-protein 
interfaces, druggable pockets displaying characteristics 
closely related to the ones forming catalytic sites can be 
found (Fig. 2). 
  Crude structural analysis of experimental protein-protein 
complex could initially give the impression that the topo-
logical features present within the interface will not favor the 
efficient and selective binding of a small molecule able to 
interfere with the formation or the stabilization of a macro-
molecular complex. Clearly, the interaction surface involved 
is rather large (700-1500 Å
2) and the binding surfaces tend to 
be relatively flat [36, 38]. However it was suggested that the 
size of the interaction patch of residues present at the inter-
face is not systematically meant to be covered by the small 
molecule [39], but rather that the binding of a drug in one 
specific region of the interface could be enough to perturb 
complex formation or to the opposite, stabilize an interac-
tion. For example, the subset of the interface that contributes 
to high-affinity is much smaller [39] than the interface itself 
and it is not significantly bigger than that of a standard 
“drug-like” molecule [40-42] (Fig. 3). Consistent with this 
view, the existence of “hot-spots” have been introduced by 
Wells and co-workers [40] some 15 years ago. Using alanine 
scanning mutagenesis experiments on human growth hor-
mone and its receptor, they demonstrated that even though 
the binding interface is quite large, only a subset of the resi-
dues involved is directly implicated in the bulk of the bind-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The two components of virtual screening. The selection of LBVS and/or SBVS is based on the amount and type of information 
available on the target at the beginning of a screening campaign. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Five cavities detected by PocketPicker [37] on MDM2. 
The predicted deepest and largest pocket (blue arrow) is indeed the 
key binding site for p53 and small molecules impeding p53 bind-
ing. Red spheres represent regions that are more buried in the pro-
tein interior as opposed to blue spheres, that become fully solvent 
exposed when the color shift to navy blue. 32    The Open Biochemistry Journal, 2008, Volume 2  Sperandio et al. 
ing energy. Therefore, the perspective of finding small mole-
cules that specifically interact with those hot-spots revived 
the pursuit of protein-protein interaction antagonists (and 
possibly agonists). Since, a lot of work has been put through 
the characterization of the hot-spot regions.  
  For instance, Bogan and Thorn have examined 2325 
alanine mutants for which changes in the binding free energy 
have been measured, and showed that the energetic contribu-
tions of the individual side chains did not correlate with their 
buried surface [43]. In several cases, a set of energetically 
unimportant contacts surrounded the hot-spots and appeared 
to occlude bulk-solvent access by formation of what was 
called an “O-ring” [44]. From their work it was furthermore 
concluded that certain amino-acids were more present in the 
observed hot-spots, noticeably tryptophan (21%), arginine 
(13%), and tyrosine (12%) than other amino acids such as 
leucine, methionine, serine, threonine, and valine each of 
which accounted for less than 3% of all hot-spot residues 
[45]. However, these observations do not apply to all com-
plexes, it for instance depends if they are permanent or tran-
sient. Stites et al [46] studied the thermodynamics of protein-
protein association and pointed out that hydrophobic interac-
tions generally provide the key driving forces for many pro-
tein-protein complex formations, suggesting that it could be 
difficult to counteract this event with a small drug-like mole-
cule. To bind, a small compound usually requires a cavity, 
that pre-exists, at the interface, or that is formed during the 
protein-drug or protein-protein interaction. The presence of a 
cavity at, or next to the interface, containing (or in the vicin-
ity of) the hot-spot residues is thus usually required to launch 
in silico screening experiments. Other difficulties with tar-
geting PPIs come from possible flexibility at the interface. 
While active site regions tend to be relatively rigid and well 
formed, protein interface regions can undergo conforma-
tional changes that are rather difficult to predict, thereby, in 
some situations, impeding the rational design of drug-like 
inhibitors or stabilizers through available in silico proce-
dures. Thus, two main problems generally have to be solved 
by the drug designers aiming at interfering with PPIs. First, 
the identification of a suitable region on the 3D structure of a 
protein or of a complex and second a way to investigate the 
flexibility of the region (this can also apply to catalytic sites, 
of course but it may be less acute). Interesting zones can be 
pinpointed through hot-spot/binding site predictions, data 
mining, structural analysis, protein docking combined with 
for instance site directed mutagenesis experiments [47-49]. 
Next, the ability of a protein to bind another protein usually 
involves a series of pharmaco-topological complementarities 
that can require minor to important conformational changes 
[50, 51]. These changes can be very difficult to assess ex-
perimentally or in silico. Nevertheless computer methods 
such as normal modes, gaussian network model, and molecu-
lar dynamics can be applied [52]. 
Protein-Protein Inhibition Success Stories 
  In spite of the difficulties mentioned above, several pre-
viously reported small molecules are able to interfere with 
PPIs. These encouraging studies are likely to be followed by 
many such investigations in the near future, paving the way 
for the design of new therapeutic compounds. The chemical 
compounds that can mediate the perturbation of the interac-
tion act either directly, through an inhibition of the protein-
protein binding or indirectly, via the binding to an allosteric 
site and the distant induction of a perturbation signal that 
will promote conformational changes and impede binding. In 
oncology, a recent set of exiting targets has emerged with 
reported inhibitors showing sufficient potency and intracellu-
lar activity to address the biological challenge and to start 
acting on the diseases. Most of the recently identified targets 
in oncology are characterized by the interaction between a 
linear region of one partner and a hydrophobic cleft on the 
other [7]. Several of the biological systems concerned by 
these investigations have focused on cancer, but not exclu-
sively [53]. Specific examples can be cited here, like 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Examples of “drug-like” protein-protein antagonists. Screening Outside the Catalytic Site  The Open Biochemistry Journal, 2008, Volume 2    33 
MDM2-p53, Bcl-XL-Bak, IL-2-IL-2R, LFA-1-ICAM1, 
Ras-Raf, XIAP-smac, TNF-TNFRc1 [38].  
Applications of in Silico Screening to PPIs 
  In the following, we will limit ourselves to a situation 
where structure-based ligand screening methods can be ap-
plied. In fact HTS is not always well-suited for screening 
protein-protein interaction because of difficulties setting-up 
the assays, among others. As such, a better solution in terms 
of costs and efficacy could be to first use in silico screening 
methods followed by low or medium throughput assay for-
mats. 
  A well-known example of a macromolecular complex 
that has been investigated through computational studies is 
the p53-MDM2 complex. In this case, the flexibility-
induced-fit problem is not really present and the druggable 
cavity appears to be pre-formed on one partner, allowing the 
direct use of virtual screening strategies. The p53 tumor sup-
pressor is central to the regulation of cell cycle progression, 
DNA repair, and apoptosis and is an attractive therapeutic 
target because its tumor suppressor activity can be employed 
to eradicate tumor cells [54]. The complex is characterized 
by the interaction of a short helix in the N-terminus of p53 
and a small, deep hydrophobic pocket in MDM2 [55]. Typi-
cally, the pocket in MDM2 represents an attractive site to 
block the p53-MDM2 interaction. Lu et al [56] have indeed 
used this pocket and available crystal structures with cocrys-
talized small-molecules to perform a two-step computational 
study. First, they derived from the cocrystalized small-
molecules a three-point-pharmacophore based on three hy-
drophobic spots, that they used to screen the National Cancer 
Institute (NCI)’s 3D database in order to obtain an initial list 
of hits. Second, they docked these hits to the p53 site in 
MDM2. The study has allowed the identification of a novel 
inhibitor with a Ki of 120 nM with respect to a Ki of 6670 
nM for the natural binder p53 in the same assay. 
  However, it should be born in mind that some other pro-
tein complexes are much more challenging to target. A clear 
example that illustrates the difficulties of targeting PPIs (but 
which also applies to catalytic pocket to some extent) is the 
case of the IL-2-IL-2R receptor complex. In this macromo-
lecular complex, the presence of an equilibrium between 
several conformations has been observed and small mole-
cules have been determined that prevent the interaction be-
tween IL-2 and its receptor IL-2R by binding to IL-2. Inter-
estingly, the inhibitory efficiency of the ligands is due to 
binding to small cavities on IL-2 inaccessible to IL-2R. The 
ligands possess a similar but more localized electrostatic 
field as compared to the IL-2R receptor, and target the 
same hot-spots than the one used by the receptor for binding 
IL-2 [57]. IL-2R completely envelops the footprint covered 
by these small-molecule competitive inhibitors. However, 
the conformation of these hot-spots on the IL-2 side is dif-
ferent depending on which partner binds to IL-2. Therefore, 
there are multiple tight binding complex conformations at 
these common and adaptive hot-spots [57]. This result al-
lows researchers to envision more drug discovery perspec-
tives than the availability of static structures only permits, 
however a rational and cost-effective way to perform such 
tasks remain challenging. The kind of perspective we can 
draw from the IL-2-IL2R case is two-fold. First, the in-
duced-fit of biomolecules when bound to a given partner can 
be specific for this partner, which brings more complexity to 
the system that is being studied. Second, the X-ray structure 
may in case of induced-fit not be the ideal source of topo-
logical information in terms of what is to be called a binding 
site per se (i.e. a cavity large enough to fit a small molecule). 
This means, that the sole rigid surface of the receptor crystal-
lographic structure cannot be the ultimate element to deter-
mine whether a structure-based project is feasible or not, but 
rather it could be wise to combine the information with pre-
viously mentioned computer tools, such as normal mode 
analysis and molecular dynamics. In fact, in order to try to 
address the flexibility problem, the main protocols currently 
applied can be summarized as follow [14]. The first ap-
proach involves the use of soft potentials, where some atom 
overlaps are tolerated. Another way is to dock on multiple 
structures (experimental or simulated) of the receptor. The 
ultimate approach would be to explicitly consider protein 
and ligand flexibility during docking. Yet, this latter ap-
proach is very computationally demanding and, for the time 
being, basically no packages are able to address the problem 
efficiently in the context of high-throughput docking, while 
molecular dynamics could be run on each docked ligand and 
somewhat could allow both, flexibility of the receptor and of 
the ligands. The problem of performing docking against mul-
tiple receptor conformations lies with how to deal with the 
ranked lists since for each structure of the receptor, the dock-
ing/scoring procedure can propose over 1000 likely mole-
cules. If this computation is performed on 3 structures, one 
may have a list of 3000 molecules to test experimentally 
with possibly very few consensus compounds. The merge-
and-shrink procedure has been recently proposed to address 
this problem [58]. With this approach, for each compound, 
the best rank -not the best score- is kept. This was shown 
efficient on some targets but, in general, to use this ap-
proach, one needs known actives to test the protocol and 
calibrate the computations. The merge-and-shrink protocol 
can thus be efficient in some cases or dilute the correct re-
sults for some targets. As such, much work is needed to ad-
dress this difficult question of flexibility from the receptor 
side. Interestingly, a recent molecular dynamics study inves-
tigating transient pockets on protein surfaces directly located 
at the PPIs has been reported [38]. The authors investigated 
BCL-Xl, IL-2 and MDM2 and proposed a new pocket detec-
tion protocol. They observed that the native inhibitor-binding 
pocket was partly present in the unbound proteins. They per-
formed 10 ns molecular dynamics simulations and scanned, 
on many structural snapshots collected along the trajectory, 
the surface of the proteins, in search of transient or more 
permanent cavities. They noticed that some cavities were 
opening up within 2.5 ps and that most of them appeared 
multiple times. In the druggable region, they noticed that 
pockets of similar size as compared with the experimental 
structures in complex with the ligand could be generated. 
Docking was successfully performed into these transient 
pockets, suggesting that this protocol is viable to study pro-
tein interfaces with the goal of designing antagonists and 
possibly stabilizers although it remains to be fully demon-
strated if this approach is viable in a real life situation, with a 
large compound collection and the need to select a small list 
for in vitro testing. Thus, it would be interesting to apply 
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the context of high-throughput docking/scoring in order to 
see if it is possible to find interaction inhibitors via such   
protocols. 
Rational Inhibition of Transient Protein-Membrane In-
teractions 
  Based on recent investigation of PPIs and their potential 
as targets for therapeutic interventions, one might consider 
targeting other kinds of macromolecular interactions such as 
transient protein-membrane interaction. In our recent study 
of the interaction between the discoidin C2 domain of coagu-
lation factor Va and the platelet membrane [19], we sug-
gested to enlarge the vision we have regarding the develop-
ment of therapeutic compounds by applying the initial steps 
of the drug discovery machinery to this hitherto neglected 
interaction class.  
  Research in the past decade has revealed that many cyto-
solic proteins are recruited to different cellular membranes to 
form protein-protein and lipid-protein interactions during 
cell signaling and membrane trafficking. Membrane assem-
bly of these peripheral proteins is mediated by a growing 
number of modular membrane targeting domains, including 
C1, C2, PH, FYVE, PX, ENTH, ANTH, BAR, FERM, and 
tubby domains, that recognize specific lipid molecules in the 
membranes [59]. However, the mechanisms by which these 
domains and their host proteins are recruited to and interact 
with various cell membranes are only beginning to be unrav-
eled [59]. Among these protein domains, we analyzed the 
structure of several protein domains known to be involved in 
membrane interaction, namely, the discoidin C2 domain of 
coagulation factor Va [60], plasma beta-2 glycoprotein 1 
[61], cyclooxygenase [62], PX domain [63], and the tubby-
protein [64]. We found, in agreement with a recent bioin-
formatics study [65] that these membrane-binding regions 
possess specific chemical and topological properties such as 
cationic patches that are surrounded by aromatic and ali-
phatic clusters capable of interaction with phospholipids 
head groups. In addition, we noticed that a druggable pocket 
[19] (Fig. 4) was present at the expected protein-membrane 
interface region (or nearby) which suggests that inhibition of 
membrane-binding (possibly stabilization but this needs new 
investigations) could be addressed via combined in silico-in 
vitro procedures.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Detected cavities (green) with the computer tool PASS 
[66], on Factor Va (left) and the PX-domain (right). 
  Interestingly, the size of the predicted binding pocket 
envelopes for these five membrane-binding proteins within 
the membrane-binding region ranges from 200 to 600 Å
3, 
values commonly computed for proteins co-crystallized with 
drug-like ligands [67]. 
  As a proof of concept, we decided to study the discoidin 
C2 domain of FVa, and tried to identify drug-like molecules 
that have the capacity to prevent the interaction of this do-
main with a relevant membrane surface (Fig. 4) using in 
silico screening, functional assays and surface plasmon reso-
nance (SPR) [19]. The C2 domain of coagulation FV can be 
considered as a representative protein domain involved in 
calcium-independent membrane binding. This domain is 
closely related, structurally and functionally, to the C2 do-
main of factor VIII (FVIII, a protein involved in hemophilia 
A) [68]. Although this domain is named C2, this region of 
FV or FVIII is structurally unrelated to the so-called C2 do-
main of for instance cytosolic phospholipase A2. FV and 
FVIII are homologous molecules that share a domain archi-
tecture A1-A2-B-A3-C1-C2. The binding of coagulation FV 
(via at least its C2 domain) to activated membranes of circu-
lating platelets is essential for the expression of its functions 
in coagulation. Upon activation by thrombin, activated FV 
(FVa) acts as a cofactor of activated factor X (FXa) in the 
prothrombinase (PTase) complex, which converts prothrom-
bin to thrombin on an appropriate phospholipid surface [69]. 
Excess thrombin formation can lead to thrombotic events 
[70], suggesting that small inhibitors of FV-membrane inter-
actions could be the starting point for the development of a 
novel class of antithrombotic drugs. The FV C2 domain 
comprises a distorted jelly-roll -barrel motif consisting of 
eight major anti-parallel strands arranged in two -sheets. 
Several loops, presenting hydrophobic/aromatic residues, 
facilitate immersion of the C2 domain into the membrane 
[71]. Specific interactions with phosphatidylserine (PS) head 
groups have been postulated to occur in the groove enclosed 
by these membrane-binding loops [60]. This zone is sur-
rounded by several basic residues, which facilitate the for-
mation of an encounter complex with the negatively-charged 
membrane phosphate groups via electrostatic steering, and 
that anchor the module into the membrane bilayer. The FV 
membrane-binding loops can assume an open or a closed 
conformation (Fig. 5) and it is believed (but not proven) that 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). The two known conformations of the discoidin C2 domain 
of coagulation factor Va, open (magenta) and closed (blue). Screening Outside the Catalytic Site  The Open Biochemistry Journal, 2008, Volume 2    35 
the closed form has low membrane affinity whereas the open 
form is suitable for membrane interaction. In the open crystal 
form, the exposed indoles of Trp 2063 and Trp 2064 con-
tribute to the immersion of the module by interaction with 
the apolar membrane core. The nearby-predicted druggable 
pocket is lined with polar/basic/aliphatic/aromatic side 
chains (Ser 2183, Gln 2085, Lys 2060, Trp 2068, Met 2120, 
Ser 2115, Leu 2116, Arg 2080) ideally arranged for interac-
tions with lipid headgroups. 
  SB-VLS methods help to prioritize large compound col-
lections prior to experimental testing. We applied our vali-
dated multi-step SB-VLS protocol [72] to both, the open and 
closed C2 crystal forms and selected the best 500 molecules 
for each receptor form (i.e., we decided to screen around 
1000 compounds in total). This hierarchical screening proto-
col starts with using a relatively large compound collection 
(of about 500,000 molecules in 2D) obtained from a chemi-
cal vendor (in the present case it was ChemBridge [73]). 
Some molecules that do not appear to have a drug-like pro-
file or that contain reactive groups are removed using several 
soft ADME/Tox filtering steps [74]. It is important to note 
that at this level of investigation, the filtering was relatively 
soft in order to keep a significant number of molecules for 
the subsequent phases of the procedure. After this 
ADME/Tox step, about 200,000 molecules were removed 
and the remaining compounds were transformed to a multi-
conformer collection in 3D. Each compound was docked as a 
rigid body and the molecules that had the best shape com-
plementarity with the receptor were kept for an additional 
flexible docking step. This latter used an incremental con-
struction algorithm as implemented in the Surflex package 
[75, 76]. Subsequently, the highest-ranking molecules in 
term of predicted affinity (scores) were selected for experi-
mental assays. We screened experimentally 1018 molecules 
and we initially studied their ability to inhibit prothrombin 
activation. Nine molecules were identified that inhibited a 
prothrombinase assay by more than 99% at a concentration 
of 100 μM. Two molecules were inhibiting the assay system 
via a membrane-independent mechanism but seven mole-
cules remained, apparently selectively inhibiting the FV-
membrane interaction (see an example Fig. 6). To confirm 
that these compounds were impeding the association be-
tween of FV C2 domain with the membrane, we performed 
surface plasmon resonance (SPR) experiments. Results of 
these direct binding analyses confirmed that the small mole-
cules were indeed inhibiting the protein-membrane interac-
tion and we noticed that four out of the seven hit compounds 
also inhibited membrane binding of the structurally related 
blood coagulation FVIII.  
  It is interesting to note that the only protein-membrane 
HTS study published to date was performed on factor VIII, 
with a compound collection subset of 10,000 molecules ex-
tracted from the ChemBridge library [73]. Thus, after com-
pletion of our FV study, we decided to perform control in 
silico experiments on the FVIII C2 domain to further vali-
date the concept of using in silico screening computations 
before in vitro experiments when a limited budget is at hand. 
We retrieved the X-ray structure of the FVIII C2 domain and 
applied the same VLS protocol as was used for FV, includ-
ing the FVIII inhibitors of ref. [77] in our 300,000 Chem-
Bridge ADME/tox filtered compound collection. Since the 
FVIII loops important for membrane binding are in an open 
conformation, we performed rigid body docking and flexible 
docking on this X-ray structure. We identified 5 compounds 
out of the 10 found by HTS in the top 1000 Surflex list. In 
addition, with the C2 domain of FVIII as a target we also 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Example of one small molecule identified in the FV-membrane study that impedes protein-membrane interaction, it can be used as a 
mechanistic probe to investigate this molecular event or, could be used as a starting point to develop anticoagulant molecules. 36    The Open Biochemistry Journal, 2008, Volume 2  Sperandio et al. 
found 3 molecules that had previously been identified in our 
FV study and that were shown to cross-react with FVIII 
membrane binding. Thus we obtained, with our in silico ap-
proach, an overall hit rate for FVIII of at least 0.8. These 
results indicate that for FVIII, our strategy is more efficient 
than the HTS-only approach, since in this case, the hit rate 
after the initial HTS work was (10 actives/10,000) x 100 = 
0.1%.  
  The advantages of using hierarchical SB-VLS protocols 
with rigid body docking prior to flexible ligand docking is 
that the computations run significantly faster (thus can be 
carried out on only 1 workstation in about 2 weeks) as com-
pared to a full flexible ligand docking of an entire compound 
collection (about 8 weeks on the same single workstation) 
while performing better (less noise) or equally well. Possi-
bly, some active molecules are lost because of the hierarchi-
cal procedure but from our investigations, real actives are 
also lost when performing full flexible docking due to ap-
proximations in the scoring functions and errors with pose 
predictions. It would seem indeed that a rigid-body docking 
step somewhat reduces these artifacts and improves enrich-
ment. The hierarchical approach is also very interesting 
when several 3D structures of a receptor are available, since 
again, the computations can be performed on a few worksta-
tions in parallel as compared to as using full flexible dock-
ing. 
CONCLUSION 
  Screening of catalytic sites via HTS and in silico methods 
has been performed during 15 years and it is now time to 
also apply these tools to other target classes, such as protein-
protein interactions or protein-membrane interactions. The 
goal can be to find inhibitors or stabilizers of interactions, 
either to understand better a molecular mechanism (like in 
the new emerging chemogenomics projects) or with the in-
tention of developing new drugs. Experimental screening of 
difficult targets is time consuming and cost intensive but it is 
known that in silico approaches can facilitate the process. In 
this review, we advocate the use of in silico tools in order to 
target unconventional macromolecules, with a special em-
phasis on protein-membrane interaction. Therapeutic targets 
that bind transiently to membrane or protein-protein com-
plexes have been neglected thus far and remain among the 
most difficult challenges in contemporary drug discovery. In 
the case of protein-protein complexes, it can be difficult to 
apply in silico methods due to flexibility problems but new 
protocols have been reported that should facilitate undertak-
ing such projects. In the case of protein-membrane interac-
tion, the situation is also complex. For instance, the mecha-
nism of transient protein-membrane interaction is not fully 
understood, success stories are extremely rare and generic 
approaches are missing. Protein-membrane interactions are 
however crucial in many biological processes as they local-
ize and concentrate key molecular factors on specific cell 
surfaces. We have shown that combining SB-VLS experi-
ments with in vitro assays allowed for the rational discovery 
of hit compounds that are able to disrupt FV membrane-
binding activity in a timely and cost-effective fashion. These 
molecules are promising leads for the development of in 
vitro tools for hemostasis research and for the design of a 
novel class of anticoagulant drugs. It is remarkable that small 
molecules can impede membrane-binding since the binding 
interface between the membrane-binding domain and the 
phospholipids is relatively large with, in general, immersion 
of the proteins several angstroms deep into the membrane 
bilayers [71]. However, just like in the case of protein-
protein interaction [40], the bulk of the binding energy ap-
pears to be derived from contacts with just a small number of 
amino acid residues. We conclude that hierarchical virtual 
screening approaches in combination with SPR technology 
are an efficient and generally applicable approach for rou-
tinely identifying membrane-binding inhibitors. This strategy 
could therefore be applied to other relevant membrane-
binding proteins in search of the next generation of therapeu-
tics.  
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